BRCA2 and neoplasm: To this end, immunocompetent C57BL/6 mice were inoculated intraperitoneally with ID8-Trp53(−/−)Brca2(−/−) cells and treated with different doses of olaparib (5, 25, and 50 mg/kgBW) five times a week, starting at day seven after tumour implantation (Fig. 2a).